Table 1.
Tolerance of vaccine in overall population and COVID-19 + versus COVID-19 - groups
| COVID-19 + (n=61) | COVID-19 - (n=1987) | p |
Total (n=2048) |
|
|---|---|---|---|---|
| Age (mean years old) | 61.4 | 62.2 | 0.6 | 62 |
| Female n (%) | 37 (60.6) | 1206 (60.7) | 0.99 | 1243 (60.7) |
|
Side effects n (%) No side effect Local reaction Systemic reaction |
16 (26.2) 33 (54.1) 28 (45.9) |
851 (42.8) 910 (45.8) 590 (29.7) |
0.01* 0.2 0.01* |
867 (42.3) 943 (46) 618 (30.1) |
|
Asthenia n (%) Grade (mean) Duration (mean days) |
15 (25.6) 1.33 1.66 |
302 (15.2) 1.25 2.8 |
0.045* 0.54 0.37 |
317 (15.5) |
|
Headache n (%) Grade (mean) Duration (mean days) |
12 (19.7) 1.25 1.5 |
184 (9.3) 1.22 2.54 |
0.01* 0.84 0.5 |
196 (9.6) |
| Chills n (%) | 6 (9.8) | 56 (2.8) | 0.009 | 62 (3) |
| Myalgia n (%) | 4 (6.5) | 257 (12.9) | 0.17 | 261 (12.7) |
| Abdominal pain n (%) | 1 (1.6) | 29 (1.4) | 0.59 | 30 (1.5) |
| Arthralgia n (%) | 2 (3.3) | 65 (3.3) | 1 | 67 (3.3) |
| Paresthesia n (%) | 1 (1.6) | 38 (1.6) | 1 | 39 (1.9) |
| Thoracic pain n (%) | 1 (1.6) | 16 (0.8) | 0.4 | 17 (0.8) |
| Dyspnea n (%) | 1 (1.6) | 13 (0.6) | 0.34 | 14 (0.7) |
|
Fever n (%) Grade (mean) Duration (mean days) |
4 (6.5) 1.50 1.50 |
18 (0.9) 1.11 1.66 |
0.003* 0.16 0.89 |
22 (1) |
| Vomiting n (%) | 0 (0) | 2 (0.1) | 0.99 | 2 (0.09) |
| Cutaneous reaction n (%) | 1 (1.6) | 7 (0.3) | 0.2 | 8 (0.4) |
| Diarrhea n (%) | 0 (0) | 9 (0.4) | 0.99 | 9 (0.4) |
| Anosmia/Ageusia n (%) | 0 (0) | 5 (0.2) | 0.99 | 5 (0.2) |
| Local adenitis n (%) | 1 (1.6) | 4 (0.2) | 0.1 | 5 (0.2) |
| Herpes n (%) | 1 (1.6) | 1 (0.05) | 0.058 | 2 (0.09) |
| Dizziness n (%) | 0 (0) | 2 (0.1) | 0.99 | 2 (0.09) |
|
Grade of side effect n (%) Grade 0 Grade 1 Grade 2 Grade 3 |
16 (26.2) 36 (59) 8 (13.1) 1 (1.6) |
851 (42.8) 953 (48) 159 (8) 24 (1.2) |
0.03* |
867 (41.3) 989 (48.3) 167 (8.1) 25 (1.2) |
| Number of side effects (mean) | 1.45 | 0.96 | 0.0016* | 0.98 |
| Sum of grade of side effects (mean) | 1.75 | 1.14 | 0.006* | 1.16 |
*p<0.05.